Treatment of acute antibody-mediated rejection using Rituximab
- سال انتشار: 1396
- محل انتشار: فصلنامه بین المللی تحقیقات پزشکی، دوره: 6، شماره: 3
- کد COI اختصاصی: JR_INTJMI-6-3_007
- زبان مقاله: انگلیسی
- تعداد مشاهده: 330
نویسندگان
Department of Nephrology, Clinical Research Development Unit (CRDU), Sayad Shirazi hospital, GolestanUniversity of Medical Sciences, Gorgan, Iran.
Department of Radiology, Clinical Research Development Unit (CRDU), Sayad Shirazi hospital, GolestanUniversity of Medical Sciences, Gorgan, Iran
Medical Student, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
Dentistrystudent,studentresearchcommittee,MazandaranUniversityofmedicalscience,sari,Iran
چکیده
Introduction: One of the optimal therapies for most of the end-stage renal disease (ESRD) patients istransplantation. Acute Antibody Mediated Rejection is one type of acute rejection in which antibodies aredirected against donor specific human leukocyte antigen (HLA). Rituximab is one kind of the drugs usedfor AMR treatment based on elimination of circulating Ab. It is a chimeric monoclonal Ab which isspecific for human B lymphocyte– restricted differentiation antigen (CD20). Concerning the incidence ofAMR in transplantation, existence of resistance to usual AMR therapy and their poor outcomes, wedecided to use Rituximab (RTX) in treatment of AMR and to study its outcomes. Material/Patients: Allpatients who underwent renal transplantation from 2009 to 2014 in Chamran and Labbafinejad centersenrolled. these patients further receiving conventional therapy AMR (tacrolimus + Cellcept +corticosteroids ± PP), were treated with one or two dosage of RTX 500mg and the graft s response andthe patient s response to RTX were studied. Results: After 5-11 months follow-up, patients’ survival was100% and grafts survival was 77%. In 17 patients renal function improved which the average creatinine(Cr) in the first month after treatment was 1.6+/-0.5 (P< 0.001) and the average Cr in 6 month was 1.5+/-0.8 (P< 0.001).Conclusion: In comparison with outcomes reported before in treatment of AMR, our studyobtained excellent outcomes in patient and graft survival (100% and 77% respectively). Our findingssuggest that the usage of RTX in the treatment of AMR at least in short and medium term may beeffective.کلیدواژه ها
Rituximab, Renal Transplantation, Acute Antibody-Mediated Rejectionاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.